{"transactions":[{"id":4638153,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-10-08T22:27:56.000Z","date":"2026-10-08","kind":"purchase","planned":false,"acquired":true,"shares":2256,"price":1.3283,"value":2996.6448,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.3200 to $1.3300, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":945924,"source":{"system":"sec-edgar","filing":"0001940272-26-000023","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000023/primary_doc.xml","form_type":"4"}},{"id":4638152,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-10-08T22:27:56.000Z","date":"2026-10-07","kind":"purchase","planned":false,"acquired":true,"shares":3046,"price":1.33,"value":4051.18,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":943668,"source":{"system":"sec-edgar","filing":"0001940272-26-000023","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000023/primary_doc.xml","form_type":"4"}},{"id":4638151,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-10-08T22:27:56.000Z","date":"2026-10-06","kind":"purchase","planned":false,"acquired":true,"shares":5601,"price":1.3277,"value":7436.4477,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.3200 to $1.3300, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":940622,"source":{"system":"sec-edgar","filing":"0001940272-26-000023","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000023/primary_doc.xml","form_type":"4"}},{"id":4630729,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-10-05T21:11:48.000Z","date":"2026-10-05","kind":"purchase","planned":false,"acquired":true,"shares":18182,"price":1.33,"value":24182.06,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":935021,"source":{"system":"sec-edgar","filing":"0001940272-26-000022","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000022/primary_doc.xml","form_type":"4"}},{"id":4630728,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-10-05T21:11:48.000Z","date":"2026-10-02","kind":"purchase","planned":false,"acquired":true,"shares":8307,"price":1.33,"value":11048.31,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":916839,"source":{"system":"sec-edgar","filing":"0001940272-26-000022","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000022/primary_doc.xml","form_type":"4"}},{"id":4630727,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-10-05T21:11:48.000Z","date":"2026-10-01","kind":"purchase","planned":false,"acquired":true,"shares":16431,"price":1.3298,"value":21849.9438,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.3200 to $1.3300, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":908532,"source":{"system":"sec-edgar","filing":"0001940272-26-000022","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000022/primary_doc.xml","form_type":"4"}},{"id":4620098,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-09-16T22:58:22.000Z","date":"2026-09-16","kind":"purchase","planned":false,"acquired":true,"shares":8340,"price":1.289,"value":10750.26,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.2600 to $1.3000, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":892101,"source":{"system":"sec-edgar","filing":"0001940272-26-000021","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000021/primary_doc.xml","form_type":"4"}},{"id":4620097,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-09-16T22:58:22.000Z","date":"2026-09-15","kind":"purchase","planned":false,"acquired":true,"shares":54256,"price":1.2984,"value":70445.9904,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.2800 to $1.3000, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":883761,"source":{"system":"sec-edgar","filing":"0001940272-26-000021","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000021/primary_doc.xml","form_type":"4"}},{"id":4620096,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-09-16T22:58:22.000Z","date":"2026-09-14","kind":"purchase","planned":false,"acquired":true,"shares":28505,"price":1.2938,"value":36879.769,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.2900 to $1.3100, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":829505,"source":{"system":"sec-edgar","filing":"0001940272-26-000021","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000021/primary_doc.xml","form_type":"4"}},{"id":3548219,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-08T21:16:27.000Z","date":"2026-09-03","kind":"purchase","planned":false,"acquired":true,"shares":900000,"price":1.7824,"value":1604160.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7800 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":6524151,"source":{"system":"sec-edgar","filing":"0001940272-26-000020","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000020/primary_doc.xml","form_type":"4"}},{"id":1159,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-02T21:52:43.000Z","date":"2026-09-02","kind":"purchase","planned":false,"acquired":true,"shares":187704,"price":1.7985,"value":337585.644,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7750 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":5624151,"source":{"system":"sec-edgar","filing":"0001940272-26-000019","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000019/primary_doc.xml","form_type":"4"}},{"id":1158,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-02T21:52:43.000Z","date":"2026-09-01","kind":"purchase","planned":false,"acquired":true,"shares":179058,"price":1.7959,"value":321570.2622,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7700 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":5436447,"source":{"system":"sec-edgar","filing":"0001940272-26-000019","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000019/primary_doc.xml","form_type":"4"}},{"id":1157,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-02T21:52:43.000Z","date":"2026-08-31","kind":"purchase","planned":false,"acquired":true,"shares":403571,"price":1.7905,"value":722593.8755,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7700 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":5257389,"source":{"system":"sec-edgar","filing":"0001940272-26-000019","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000019/primary_doc.xml","form_type":"4"}},{"id":678248,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-24T22:12:58.000Z","date":"2026-08-24","kind":"purchase","planned":false,"acquired":true,"shares":107374,"price":1.7542,"value":188355.4708,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7000 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":4853818,"source":{"system":"sec-edgar","filing":"0001940272-26-000017","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/34956/000194027226000017/primary_doc.xml","form_type":"4"}},{"id":678247,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-24T22:12:58.000Z","date":"2026-08-21","kind":"purchase","planned":false,"acquired":true,"shares":716369,"price":1.7676,"value":1266253.8444,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7250 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":4746444,"source":{"system":"sec-edgar","filing":"0001940272-26-000017","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000194027226000017/primary_doc.xml","form_type":"4"}},{"id":678246,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-24T22:12:58.000Z","date":"2026-08-20","kind":"purchase","planned":false,"acquired":true,"shares":202124,"price":1.7788,"value":359538.1712,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7650 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":4030075,"source":{"system":"sec-edgar","filing":"0001940272-26-000017","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000194027226000017/primary_doc.xml","form_type":"4"}},{"id":699027,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-03T21:53:07.000Z","date":"2026-07-31","kind":"purchase","planned":false,"acquired":true,"shares":8003,"price":4.8,"value":38414.4,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":722419,"source":{"system":"sec-edgar","filing":"0001940272-26-000013","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000013/primary_doc.xml","form_type":"4"}},{"id":699026,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-03T21:53:07.000Z","date":"2026-07-31","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":4.9816,"value":124540.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9740 to $4.9824, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":714416,"source":{"system":"sec-edgar","filing":"0001940272-26-000013","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000013/primary_doc.xml","form_type":"4"}},{"id":699025,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-03T21:53:07.000Z","date":"2026-07-31","kind":"purchase","planned":false,"acquired":true,"shares":3300,"price":4.9758,"value":16420.14,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9100 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":689416,"source":{"system":"sec-edgar","filing":"0001940272-26-000013","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000013/primary_doc.xml","form_type":"4"}},{"id":699024,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-03T21:53:07.000Z","date":"2026-07-30","kind":"purchase","planned":false,"acquired":true,"shares":77850,"price":4.9556,"value":385793.46,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.7563 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":686116,"source":{"system":"sec-edgar","filing":"0001940272-26-000013","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000013/primary_doc.xml","form_type":"4"}},{"id":699023,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-03T21:53:07.000Z","date":"2026-07-30","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":4.9,"value":490000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":608266,"source":{"system":"sec-edgar","filing":"0001940272-26-000013","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000013/primary_doc.xml","form_type":"4"}},{"id":699022,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-03T21:53:07.000Z","date":"2026-07-30","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":4.8135,"value":120337.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.8100 to $4.8450, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":508266,"source":{"system":"sec-edgar","filing":"0001940272-26-000013","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000013/primary_doc.xml","form_type":"4"}},{"id":699021,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-03T21:53:07.000Z","date":"2026-07-30","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":5,"value":100000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":483266,"source":{"system":"sec-edgar","filing":"0001940272-26-000013","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000013/primary_doc.xml","form_type":"4"}},{"id":699020,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-03T21:53:07.000Z","date":"2026-07-30","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":5,"value":100000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":463266,"source":{"system":"sec-edgar","filing":"0001940272-26-000013","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000013/primary_doc.xml","form_type":"4"}},{"id":699019,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-03T21:53:07.000Z","date":"2026-07-30","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":4.9723,"value":248615.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9000 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":443266,"source":{"system":"sec-edgar","filing":"0001940272-26-000013","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000013/primary_doc.xml","form_type":"4"}},{"id":701556,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-29T22:18:59.000Z","date":"2026-07-29","kind":"purchase","planned":false,"acquired":true,"shares":1600,"price":5,"value":8000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":393266,"source":{"system":"sec-edgar","filing":"0001940272-26-000012","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000012/primary_doc.xml","form_type":"4"}},{"id":701555,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-29T22:18:59.000Z","date":"2026-07-29","kind":"purchase","planned":false,"acquired":true,"shares":1810,"price":5,"value":9050.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":391666,"source":{"system":"sec-edgar","filing":"0001940272-26-000012","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000012/primary_doc.xml","form_type":"4"}},{"id":701554,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-29T22:18:59.000Z","date":"2026-07-28","kind":"purchase","planned":false,"acquired":true,"shares":6400,"price":4.9496,"value":31677.44,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9000 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":389856,"source":{"system":"sec-edgar","filing":"0001940272-26-000012","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000012/primary_doc.xml","form_type":"4"}},{"id":701553,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-29T22:18:59.000Z","date":"2026-07-27","kind":"purchase","planned":false,"acquired":true,"shares":7798,"price":4.9994,"value":38985.3212,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":383456,"source":{"system":"sec-edgar","filing":"0001940272-26-000012","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000012/primary_doc.xml","form_type":"4"}},{"id":707014,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-07-17T23:29:29.000Z","date":"2026-07-15","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":1.555,"value":1555.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":801000,"source":{"system":"sec-edgar","filing":"0001940272-26-000010","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000010/primary_doc.xml","form_type":"4"}},{"id":768196,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-05-21T21:08:05.000Z","date":"2026-05-19","kind":"purchase","planned":false,"acquired":true,"shares":200000,"price":1.499,"value":299800.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.4350 to $1.5700, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":800000,"source":{"system":"sec-edgar","filing":"0001940272-26-000008","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000008/primary_doc.xml","form_type":"4"}},{"id":768195,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-05-21T21:08:05.000Z","date":"2026-05-19","kind":"purchase","planned":false,"acquired":true,"shares":200000,"price":1.5604,"value":312080.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.5100 to $1.6000, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":600000,"source":{"system":"sec-edgar","filing":"0001940272-26-000008","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000008/primary_doc.xml","form_type":"4"}},{"id":768194,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-05-21T21:08:05.000Z","date":"2026-05-19","kind":"purchase","planned":false,"acquired":true,"shares":68551,"price":1.5998,"value":109667.8898,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.5700 to $1.6000, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":400000,"source":{"system":"sec-edgar","filing":"0001940272-26-000008","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000008/primary_doc.xml","form_type":"4"}},{"id":770208,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-21T00:45:33.000Z","date":"2026-05-19","kind":"purchase","planned":false,"acquired":true,"shares":200,"price":13.8,"value":2760.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC and separately managed accounts of ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":926352,"source":{"system":"sec-edgar","filing":"0001104659-26-064729","document":"tm2615289-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000110465926064729/tm2615289-1_4seq1.xml","form_type":"4"}},{"id":770207,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-21T00:45:33.000Z","date":"2026-05-19","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":13.9822,"value":139822.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.9350 to $14.0000, inclusive. Each Reporting Person undertakes to provide to Rallybio Corp, any security holder of Rallybio Corp or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC and separately managed accounts of ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":926152,"source":{"system":"sec-edgar","filing":"0001104659-26-064729","document":"tm2615289-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000110465926064729/tm2615289-1_4seq1.xml","form_type":"4"}},{"id":770206,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-21T00:45:33.000Z","date":"2026-05-18","kind":"purchase","planned":false,"acquired":true,"shares":6009,"price":13.9759,"value":83981.1831,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.9100 to $14.0000, inclusive. Each Reporting Person undertakes to provide Rallybio Corp, any security holder of Rallybio Corp or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC and separately managed accounts of ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":916152,"source":{"system":"sec-edgar","filing":"0001104659-26-064729","document":"tm2615289-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000110465926064729/tm2615289-1_4seq1.xml","form_type":"4"}},{"id":777280,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-16T00:49:37.000Z","date":"2026-05-15","kind":"purchase","planned":false,"acquired":true,"shares":200,"price":13.95,"value":2790.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC and separately managed accounts of ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":910143,"source":{"system":"sec-edgar","filing":"0001104659-26-062883","document":"tm2614866-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000110465926062883/tm2614866-1_4seq1.xml","form_type":"4"}},{"id":777279,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-16T00:49:37.000Z","date":"2026-05-15","kind":"purchase","planned":false,"acquired":true,"shares":100,"price":13.8,"value":1380.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC and separately managed accounts of ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":909943,"source":{"system":"sec-edgar","filing":"0001104659-26-062883","document":"tm2614866-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000110465926062883/tm2614866-1_4seq1.xml","form_type":"4"}},{"id":777278,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-16T00:49:37.000Z","date":"2026-05-13","kind":"purchase","planned":false,"acquired":true,"shares":75178,"price":14,"value":1052492.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC and separately managed accounts of ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":909843,"source":{"system":"sec-edgar","filing":"0001104659-26-062883","document":"tm2614866-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000110465926062883/tm2614866-1_4seq1.xml","form_type":"4"}},{"id":777277,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-16T00:49:37.000Z","date":"2026-05-13","kind":"purchase","planned":false,"acquired":true,"shares":4081,"price":13.7993,"value":56314.9433,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.7700 to $13.8000, inclusive. Each Reporting Person undertakes to provide to Rallybio Corp, any security holder of Rallybio Corp or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC and separately managed accounts of ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":834665,"source":{"system":"sec-edgar","filing":"0001104659-26-062883","document":"tm2614866-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000110465926062883/tm2614866-1_4seq1.xml","form_type":"4"}},{"id":781000,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-14T01:22:58.000Z","date":"2026-05-12","kind":"purchase","planned":false,"acquired":true,"shares":800,"price":13.8288,"value":11063.04,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.7500 to $13.9300, inclusive. Each Reporting Person undertakes to provide to Rallybio Corp, any security holder of Rallybio Corp or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC and separately managed accounts of ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":830584,"source":{"system":"sec-edgar","filing":"0001104659-26-060513","document":"tm2614593-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000110465926060513/tm2614593-1_4seq1.xml","form_type":"4"}},{"id":780999,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-14T01:22:58.000Z","date":"2026-05-11","kind":"purchase","planned":false,"acquired":true,"shares":19900,"price":14,"value":278600.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC and separately managed accounts of ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":829784,"source":{"system":"sec-edgar","filing":"0001104659-26-060513","document":"tm2614593-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000110465926060513/tm2614593-1_4seq1.xml","form_type":"4"}},{"id":780998,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-14T01:22:58.000Z","date":"2026-05-11","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":14,"value":350000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC and separately managed accounts of ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":809884,"source":{"system":"sec-edgar","filing":"0001104659-26-060513","document":"tm2614593-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000110465926060513/tm2614593-1_4seq1.xml","form_type":"4"}},{"id":780997,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-14T01:22:58.000Z","date":"2026-05-11","kind":"purchase","planned":false,"acquired":true,"shares":5100,"price":13.9984,"value":71391.84,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.9164 to $14.0000, inclusive. Each Reporting Person undertakes to provide to Rallybio Corp, any security holder of Rallybio Corp or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC and separately managed accounts of ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":784884,"source":{"system":"sec-edgar","filing":"0001104659-26-060513","document":"tm2614593-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000110465926060513/tm2614593-1_4seq1.xml","form_type":"4"}},{"id":790087,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-07T01:32:48.000Z","date":"2026-05-05","kind":"purchase","planned":false,"acquired":true,"shares":35101,"price":13.9956,"value":491259.5556,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.9100 to $14.0000, inclusive. Each Reporting Person undertakes to provide to Rallybio Corporation, any security holder of Rallybio Corporation or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC and separately managed accounts of ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":779784,"source":{"system":"sec-edgar","filing":"0001104659-26-056540","document":"tm2613874-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000110465926056540/tm2613874-2_4seq1.xml","form_type":"4"}},{"id":790086,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-07T01:32:48.000Z","date":"2026-05-04","kind":"purchase","planned":false,"acquired":true,"shares":116904,"price":13.9705,"value":1633207.332,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.8600 to $14.0000, inclusive. Each Reporting Person undertakes to provide to Rallybio Corporation, any security holder of Rallybio Corporation or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC and separately managed accounts of ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":744683,"source":{"system":"sec-edgar","filing":"0001104659-26-056540","document":"tm2613874-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000110465926056540/tm2613874-2_4seq1.xml","form_type":"4"}},{"id":790085,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-07T01:32:48.000Z","date":"2026-05-04","kind":"purchase","planned":false,"acquired":true,"shares":3900,"price":13.8978,"value":54201.42,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.8611 to $14.0000, inclusive. Each Reporting Person undertakes to provide to Rallybio Corporation, any security holder of Rallybio Corporation or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC and separately managed accounts of ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":627779,"source":{"system":"sec-edgar","filing":"0001104659-26-056540","document":"tm2613874-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000110465926056540/tm2613874-2_4seq1.xml","form_type":"4"}},{"id":1018729,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74265,"kind":"organization","name":"ADAR1 Partners, LP","position":2,"cik":"0001758866","reported_name":"ADAR1 Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74266,"kind":"organization","name":"ADAR1 Capital Management GP, LLC","position":3,"cik":"0001940267","reported_name":"ADAR1 Capital Management GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":4,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-15T13:24:20.000Z","date":"2025-10-15","kind":"sale","planned":false,"acquired":false,"shares":743358,"price":17.75,"value":13194604.5,"ownership":{"direct":false,"nature":"By Spearhead Insurance Solutions IDF, LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities to which this filing relates are held directly by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Daniel Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000902664-25-004411","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1940267/000090266425004411/ownership.xml","form_type":"4"}},{"id":1018728,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74265,"kind":"organization","name":"ADAR1 Partners, LP","position":2,"cik":"0001758866","reported_name":"ADAR1 Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74266,"kind":"organization","name":"ADAR1 Capital Management GP, LLC","position":3,"cik":"0001940267","reported_name":"ADAR1 Capital Management GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":4,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-15T13:24:20.000Z","date":"2025-10-15","kind":"sale","planned":false,"acquired":false,"shares":254669,"price":17.75,"value":4520374.75,"ownership":{"direct":false,"nature":"By ADAR1 SPVI, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities to which this filing relates are held directly by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Daniel Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000902664-25-004411","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1940267/000090266425004411/ownership.xml","form_type":"4"}},{"id":1018727,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74265,"kind":"organization","name":"ADAR1 Partners, LP","position":2,"cik":"0001758866","reported_name":"ADAR1 Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74266,"kind":"organization","name":"ADAR1 Capital Management GP, LLC","position":3,"cik":"0001940267","reported_name":"ADAR1 Capital Management GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":4,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-15T13:24:20.000Z","date":"2025-10-15","kind":"sale","planned":false,"acquired":false,"shares":4391237,"price":17.75,"value":77944456.75,"ownership":{"direct":false,"nature":"By ADAR1 Partners, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities to which this filing relates are held directly by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Daniel Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000902664-25-004411","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940267/000090266425004411/ownership.xml","form_type":"4"}},{"id":1102871,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74265,"kind":"organization","name":"ADAR1 Partners, LP","position":2,"cik":"0001758866","reported_name":"ADAR1 Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74266,"kind":"organization","name":"ADAR1 Capital Management GP, LLC","position":3,"cik":"0001940267","reported_name":"ADAR1 Capital Management GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":4,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Put Option (right to sell)","published_at":"2025-06-24T16:05:12.000Z","date":"2025-06-20","kind":"other","planned":false,"acquired":false,"shares":2,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spearhead Insurance Solutions IDF, LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":70,"exercise_date":"2024-10-01","expiration_date":"2025-06-20","underlying":"Common Stock","underlying_shares":200},"source":{"system":"sec-edgar","filing":"0001104659-25-062092","document":"tm2518715-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1940267/000110465925062092/tm2518715-1_4seq1.xml","form_type":"4"}},{"id":1102870,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74265,"kind":"organization","name":"ADAR1 Partners, LP","position":2,"cik":"0001758866","reported_name":"ADAR1 Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74266,"kind":"organization","name":"ADAR1 Capital Management GP, LLC","position":3,"cik":"0001940267","reported_name":"ADAR1 Capital Management GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":4,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Put Option (right to sell)","published_at":"2025-06-24T16:05:12.000Z","date":"2025-06-20","kind":"other","planned":false,"acquired":false,"shares":14,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By ADAR1 Partners, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":70,"exercise_date":"2024-10-01","expiration_date":"2025-06-20","underlying":"Common Stock","underlying_shares":1400},"source":{"system":"sec-edgar","filing":"0001104659-25-062092","document":"tm2518715-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1940267/000110465925062092/tm2518715-1_4seq1.xml","form_type":"4"}},{"id":1102869,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74265,"kind":"organization","name":"ADAR1 Partners, LP","position":2,"cik":"0001758866","reported_name":"ADAR1 Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74266,"kind":"organization","name":"ADAR1 Capital Management GP, LLC","position":3,"cik":"0001940267","reported_name":"ADAR1 Capital Management GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":4,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Put Option (right to sell)","published_at":"2025-06-24T16:05:12.000Z","date":"2025-06-20","kind":"other","planned":false,"acquired":false,"shares":1,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By ADAR1 Partners, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":60,"exercise_date":"2024-10-02","expiration_date":"2025-06-20","underlying":"Common Stock","underlying_shares":100},"source":{"system":"sec-edgar","filing":"0001104659-25-062092","document":"tm2518715-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1940267/000110465925062092/tm2518715-1_4seq1.xml","form_type":"4"}},{"id":1102868,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74265,"kind":"organization","name":"ADAR1 Partners, LP","position":2,"cik":"0001758866","reported_name":"ADAR1 Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74266,"kind":"organization","name":"ADAR1 Capital Management GP, LLC","position":3,"cik":"0001940267","reported_name":"ADAR1 Capital Management GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":4,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-24T16:05:12.000Z","date":"2025-06-20","kind":"other","planned":false,"acquired":false,"shares":200,"price":70,"value":14000.0,"ownership":{"direct":false,"nature":"By Spearhead Insurance Solutions IDF, LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":743358,"source":{"system":"sec-edgar","filing":"0001104659-25-062092","document":"tm2518715-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1940267/000110465925062092/tm2518715-1_4seq1.xml","form_type":"4"}},{"id":1102867,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74265,"kind":"organization","name":"ADAR1 Partners, LP","position":2,"cik":"0001758866","reported_name":"ADAR1 Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74266,"kind":"organization","name":"ADAR1 Capital Management GP, LLC","position":3,"cik":"0001940267","reported_name":"ADAR1 Capital Management GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":4,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-24T16:05:12.000Z","date":"2025-06-20","kind":"other","planned":false,"acquired":false,"shares":1400,"price":70,"value":98000.0,"ownership":{"direct":false,"nature":"By ADAR1 Partners, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":4391237,"source":{"system":"sec-edgar","filing":"0001104659-25-062092","document":"tm2518715-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1940267/000110465925062092/tm2518715-1_4seq1.xml","form_type":"4"}},{"id":1102866,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74265,"kind":"organization","name":"ADAR1 Partners, LP","position":2,"cik":"0001758866","reported_name":"ADAR1 Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74266,"kind":"organization","name":"ADAR1 Capital Management GP, LLC","position":3,"cik":"0001940267","reported_name":"ADAR1 Capital Management GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":4,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-24T16:05:12.000Z","date":"2025-06-20","kind":"other","planned":false,"acquired":false,"shares":100,"price":60,"value":6000.0,"ownership":{"direct":false,"nature":"By ADAR1 Partners, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":4392637,"source":{"system":"sec-edgar","filing":"0001104659-25-062092","document":"tm2518715-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940267/000110465925062092/tm2518715-1_4seq1.xml","form_type":"4"}},{"id":1113851,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74265,"kind":"organization","name":"ADAR1 Partners, LP","position":2,"cik":"0001758866","reported_name":"ADAR1 Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74266,"kind":"organization","name":"ADAR1 Capital Management GP, LLC","position":3,"cik":"0001940267","reported_name":"ADAR1 Capital Management GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":4,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Put Option (obligation to buy)","published_at":"2025-06-12T16:51:24.000Z","date":"2025-05-16","kind":"other","planned":false,"acquired":false,"shares":178,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spearhead Insurance Solutions IDF, LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":10,"exercise_date":"2025-04-03","expiration_date":"2025-05-16","underlying":"Common Stock","underlying_shares":17800},"source":{"system":"sec-edgar","filing":"0001104659-25-058955","document":"tm2517803-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1940267/000110465925058955/tm2517803-1_4seq1.xml","form_type":"4"}},{"id":1113850,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74265,"kind":"organization","name":"ADAR1 Partners, LP","position":2,"cik":"0001758866","reported_name":"ADAR1 Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74266,"kind":"organization","name":"ADAR1 Capital Management GP, LLC","position":3,"cik":"0001940267","reported_name":"ADAR1 Capital Management GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":4,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Put Option (obligation to buy)","published_at":"2025-06-12T16:51:24.000Z","date":"2025-05-16","kind":"other","planned":false,"acquired":false,"shares":836,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By ADAR1 Partners, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":10,"exercise_date":"2025-04-03","expiration_date":"2025-05-16","underlying":"Common Stock","underlying_shares":83600},"source":{"system":"sec-edgar","filing":"0001104659-25-058955","document":"tm2517803-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1940267/000110465925058955/tm2517803-1_4seq1.xml","form_type":"4"}},{"id":1113849,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74265,"kind":"organization","name":"ADAR1 Partners, LP","position":2,"cik":"0001758866","reported_name":"ADAR1 Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74266,"kind":"organization","name":"ADAR1 Capital Management GP, LLC","position":3,"cik":"0001940267","reported_name":"ADAR1 Capital Management GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":4,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Put Option (obligation to buy)","published_at":"2025-06-12T16:51:24.000Z","date":"2025-05-16","kind":"other","planned":false,"acquired":false,"shares":300,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By ADAR1 Partners, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":10,"exercise_date":"2025-02-27","expiration_date":"2025-05-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-25-058955","document":"tm2517803-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940267/000110465925058955/tm2517803-1_4seq1.xml","form_type":"4"}},{"id":1173473,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74265,"kind":"organization","name":"ADAR1 Partners, LP","position":2,"cik":"0001758866","reported_name":"ADAR1 Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74266,"kind":"organization","name":"ADAR1 Capital Management GP, LLC","position":3,"cik":"0001940267","reported_name":"ADAR1 Capital Management GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":4,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Cash Settled Total Return Swaps","published_at":"2025-04-11T21:57:19.000Z","date":"2025-04-09","kind":"other","planned":false,"acquired":false,"shares":74333,"ownership":{"direct":false,"nature":"By ADAR1 Partners, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"In connection with the purchase of 74,333 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 74,333 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 50,000 shares."},{"field":"kind","element":"transactionCoding","label":"F7","text":"In connection with the purchase of 74,333 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 74,333 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 50,000 shares."},{"field":"shares","element":"transactionShares","label":"F7","text":"In connection with the purchase of 74,333 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 74,333 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 50,000 shares."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"In connection with the purchase of 74,333 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 74,333 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 50,000 shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"In connection with the purchase of 74,333 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 74,333 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 50,000 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"In connection with the purchase of 74,333 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 74,333 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 50,000 shares."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F7","text":"In connection with the purchase of 74,333 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 74,333 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 50,000 shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"In connection with the purchase of 74,333 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 74,333 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 50,000 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":50000,"derivative":{"underlying":"Common Stock","underlying_shares":74333},"source":{"system":"sec-edgar","filing":"0001104659-25-034321","document":"tm2512234-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1940267/000110465925034321/tm2512234-2_4seq1.xml","form_type":"4"}},{"id":1173472,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74265,"kind":"organization","name":"ADAR1 Partners, LP","position":2,"cik":"0001758866","reported_name":"ADAR1 Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74266,"kind":"organization","name":"ADAR1 Capital Management GP, LLC","position":3,"cik":"0001940267","reported_name":"ADAR1 Capital Management GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":4,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Cash-Settled Total Return Swaps","published_at":"2025-04-11T21:57:19.000Z","date":"2025-04-09","kind":"other","planned":false,"acquired":false,"shares":500000,"ownership":{"direct":false,"nature":"By ADAR1 Partners, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"In connection with the purchase of 500,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 500,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 124,333 shares."},{"field":"kind","element":"transactionCoding","label":"F6","text":"In connection with the purchase of 500,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 500,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 124,333 shares."},{"field":"shares","element":"transactionShares","label":"F6","text":"In connection with the purchase of 500,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 500,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 124,333 shares."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"In connection with the purchase of 500,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 500,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 124,333 shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"In connection with the purchase of 500,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 500,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 124,333 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"In connection with the purchase of 500,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 500,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 124,333 shares."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F6","text":"In connection with the purchase of 500,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 500,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 124,333 shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"In connection with the purchase of 500,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 500,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 124,333 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":124333,"derivative":{"underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001104659-25-034321","document":"tm2512234-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1940267/000110465925034321/tm2512234-2_4seq1.xml","form_type":"4"}},{"id":1173471,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74265,"kind":"organization","name":"ADAR1 Partners, LP","position":2,"cik":"0001758866","reported_name":"ADAR1 Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74266,"kind":"organization","name":"ADAR1 Capital Management GP, LLC","position":3,"cik":"0001940267","reported_name":"ADAR1 Capital Management GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":4,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Cash-Settled Total Return Swaps","published_at":"2025-04-11T21:57:19.000Z","date":"2025-04-09","kind":"other","planned":false,"acquired":false,"shares":325000,"ownership":{"direct":false,"nature":"By ADAR1 Partners, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"In connection with the purchase of 325,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 325,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 624,333 shares."},{"field":"kind","element":"transactionCoding","label":"F5","text":"In connection with the purchase of 325,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 325,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 624,333 shares."},{"field":"shares","element":"transactionShares","label":"F5","text":"In connection with the purchase of 325,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 325,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 624,333 shares."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"In connection with the purchase of 325,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 325,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 624,333 shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"In connection with the purchase of 325,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 325,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 624,333 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"In connection with the purchase of 325,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 325,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 624,333 shares."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"In connection with the purchase of 325,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 325,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 624,333 shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"In connection with the purchase of 325,000 securities reported as being purchased in Table 1, ADAR1 Partners, LP and the counterparty to the cash-settled total equity swaps previously reported agreed to reduce the number of notional shares of Common Stock of the Issuer in the applicable basket by a corresponding number of 325,000 shares. As a result, the aggregate number of notional shares of Common Stock of the Issuer in the applicable basket after giving effect to such transactions is 624,333 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":624333,"derivative":{"underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001104659-25-034321","document":"tm2512234-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1940267/000110465925034321/tm2512234-2_4seq1.xml","form_type":"4"}},{"id":1173470,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74265,"kind":"organization","name":"ADAR1 Partners, LP","position":2,"cik":"0001758866","reported_name":"ADAR1 Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74266,"kind":"organization","name":"ADAR1 Capital Management GP, LLC","position":3,"cik":"0001940267","reported_name":"ADAR1 Capital Management GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":4,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T21:57:19.000Z","date":"2025-04-09","kind":"purchase","planned":false,"acquired":true,"shares":74333,"price":10.33,"value":767859.89,"ownership":{"direct":false,"nature":"By ADAR1 Partners, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":4392737,"source":{"system":"sec-edgar","filing":"0001104659-25-034321","document":"tm2512234-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1940267/000110465925034321/tm2512234-2_4seq1.xml","form_type":"4"}},{"id":1173469,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74265,"kind":"organization","name":"ADAR1 Partners, LP","position":2,"cik":"0001758866","reported_name":"ADAR1 Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74266,"kind":"organization","name":"ADAR1 Capital Management GP, LLC","position":3,"cik":"0001940267","reported_name":"ADAR1 Capital Management GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":4,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T21:57:19.000Z","date":"2025-04-09","kind":"purchase","planned":false,"acquired":true,"shares":500000,"price":10.33,"value":5165000.0,"ownership":{"direct":false,"nature":"By ADAR1 Partners, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":4318404,"source":{"system":"sec-edgar","filing":"0001104659-25-034321","document":"tm2512234-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1940267/000110465925034321/tm2512234-2_4seq1.xml","form_type":"4"}},{"id":1173468,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74265,"kind":"organization","name":"ADAR1 Partners, LP","position":2,"cik":"0001758866","reported_name":"ADAR1 Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74266,"kind":"organization","name":"ADAR1 Capital Management GP, LLC","position":3,"cik":"0001940267","reported_name":"ADAR1 Capital Management GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":4,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T21:57:19.000Z","date":"2025-04-09","kind":"purchase","planned":false,"acquired":true,"shares":325000,"price":9.857,"value":3203525.0,"ownership":{"direct":false,"nature":"By ADAR1 Partners, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.13 to $10.60, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":3818404,"source":{"system":"sec-edgar","filing":"0001104659-25-034321","document":"tm2512234-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1940267/000110465925034321/tm2512234-2_4seq1.xml","form_type":"4"}},{"id":1173467,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74265,"kind":"organization","name":"ADAR1 Partners, LP","position":2,"cik":"0001758866","reported_name":"ADAR1 Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74266,"kind":"organization","name":"ADAR1 Capital Management GP, LLC","position":3,"cik":"0001940267","reported_name":"ADAR1 Capital Management GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":4,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T21:57:19.000Z","date":"2025-04-09","kind":"purchase","planned":false,"acquired":true,"shares":16365,"price":9.3952,"value":153752.448,"ownership":{"direct":false,"nature":"By Spearhead Insurance Solutions IDF, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.21 to $9.56, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":743558,"source":{"system":"sec-edgar","filing":"0001104659-25-034321","document":"tm2512234-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1940267/000110465925034321/tm2512234-2_4seq1.xml","form_type":"4"}},{"id":1173466,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74265,"kind":"organization","name":"ADAR1 Partners, LP","position":2,"cik":"0001758866","reported_name":"ADAR1 Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74266,"kind":"organization","name":"ADAR1 Capital Management GP, LLC","position":3,"cik":"0001940267","reported_name":"ADAR1 Capital Management GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":4,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T21:57:19.000Z","date":"2025-04-09","kind":"purchase","planned":false,"acquired":true,"shares":18560,"price":9.3952,"value":174374.912,"ownership":{"direct":false,"nature":"By ADAR1 Partners, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.21 to $9.56, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"As the investment manager of ADAR1 Partners, LP and ADAR1 SPV I, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, ADAR1 SPV I, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP and ADAR1 SPV I, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and ADAR1 SPV I, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and ADAR1 SPV I, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":3493404,"source":{"system":"sec-edgar","filing":"0001104659-25-034321","document":"tm2512234-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940267/000110465925034321/tm2512234-2_4seq1.xml","form_type":"4"}},{"id":1436139,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74265,"kind":"organization","name":"ADAR1 Partners, LP","position":2,"cik":"0001758866","reported_name":"ADAR1 Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-12T22:48:13.000Z","date":"2024-08-12","kind":"purchase","planned":false,"acquired":true,"shares":757,"price":15.8824,"value":12022.9768,"ownership":{"direct":false,"nature":"By: Spearhead Insurance Solutions IDF, LLC - Series ADAR1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"ADAR1 Capital Management, LLC (\"ADAR1 Capital\"), an entity owned and controlled by Dr. Daniel Schneeberger, owns voting and investment control with respect to the shares held by Spearhead Insurance Solutions IDF, LLC - Series ADAR1 (\"Spearhead\"). Because of the relationship between Spearhead and ADAR1 Capital, ADAR1 Capital may be deemed to beneficially own the shares held directly by Spearhead."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":15067,"source":{"system":"sec-edgar","filing":"0001940272-24-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027224000006/primary_doc.xml","form_type":"4"}},{"id":1436138,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74265,"kind":"organization","name":"ADAR1 Partners, LP","position":2,"cik":"0001758866","reported_name":"ADAR1 Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-12T22:48:13.000Z","date":"2024-08-12","kind":"purchase","planned":false,"acquired":true,"shares":2243,"price":15.8824,"value":35624.2232,"ownership":{"direct":false,"nature":"By: ADAR1 Partners"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"ADAR1 Capital Management, LLC (\"ADAR1 Capital\"), an entity owned and controlled by Dr. Daniel Schneeberger, owns voting and investment control with respect to the shares held by ADAR1 Partners, LP (\"ADAR1 Partners\"). Because of the relationship between ADAR1 Partners and ADAR1 Capital, ADAR1 Capital may be deemed to beneficially own the shares held directly by ADAR1 Partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":129574,"source":{"system":"sec-edgar","filing":"0001940272-24-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027224000006/primary_doc.xml","form_type":"4"}},{"id":1436137,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74265,"kind":"organization","name":"ADAR1 Partners, LP","position":2,"cik":"0001758866","reported_name":"ADAR1 Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-12T22:48:13.000Z","date":"2024-08-09","kind":"purchase","planned":false,"acquired":true,"shares":3000,"price":14.8929,"value":44678.7,"ownership":{"direct":false,"nature":"By: ADAR1 Partners"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"ADAR1 Capital Management, LLC (\"ADAR1 Capital\"), an entity owned and controlled by Dr. Daniel Schneeberger, owns voting and investment control with respect to the shares held by ADAR1 Partners, LP (\"ADAR1 Partners\"). Because of the relationship between ADAR1 Partners and ADAR1 Capital, ADAR1 Capital may be deemed to beneficially own the shares held directly by ADAR1 Partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":127331,"source":{"system":"sec-edgar","filing":"0001940272-24-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027224000006/primary_doc.xml","form_type":"4"}}]}